Inogen (NASDAQ:INGN) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Friday.
A number of other brokerages have also commented on INGN. Zacks Investment Research lowered shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 7th. Needham & Company LLC boosted their price objective on shares of Inogen from $125.00 to $150.00 and gave the stock a “strong-buy” rating in a report on Wednesday, February 28th. Finally, Piper Jaffray Companies upgraded shares of Inogen from a “neutral” rating to an “overweight” rating in a report on Tuesday, February 20th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Inogen has a consensus rating of “Buy” and an average price target of $107.29.
Inogen (NASDAQ INGN) opened at $125.46 on Friday. The firm has a market cap of $2,646.58, a price-to-earnings ratio of 97.26, a P/E/G ratio of 3.49 and a beta of 1.03. Inogen has a 1-year low of $69.75 and a 1-year high of $134.97.
A number of hedge funds have recently modified their holdings of INGN. MetLife Investment Advisors LLC acquired a new stake in shares of Inogen in the 4th quarter valued at about $957,000. Gotham Asset Management LLC acquired a new stake in shares of Inogen in the 4th quarter valued at about $863,000. Jane Street Group LLC acquired a new stake in shares of Inogen in the 4th quarter valued at about $243,000. Meadow Creek Investment Management LLC raised its stake in shares of Inogen by 26.0% in the 4th quarter. Meadow Creek Investment Management LLC now owns 2,576 shares of the medical technology company’s stock valued at $307,000 after purchasing an additional 532 shares in the last quarter. Finally, Raymond James & Associates acquired a new stake in shares of Inogen in the 4th quarter valued at about $244,000. Hedge funds and other institutional investors own 98.19% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3255292/inogen-ingn-raised-to-buy-at-bidaskclub.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.